Poor
Mostly Aligned
Patient Risk:
Moderate
Summary
Multiple claims include numerical incidence thresholds and mechanistic phrasing that are not supported by the provided FDA label excerpts (Sections 6/5/12). Several safety-related rate claims (injection-site reactions, allergic reactions, hypertension) and the statement about absence of boxed warnings are not verifiable or unsupported from the supplied label text.
Category Scores
Accurate Statements
Emgality (galcanezumab) is a monoclonal antibody.
Supported by 11 DESCRIPTION (humanized IgG4 monoclonal antibody).
Emgality binds to the CGRP ligand.
Supported by 12.1 Mechanism of Action (binds to CGRP ligand).
Emgality prevents CGRP from activating CGRP receptors.
Supported in concept by 12.1 Mechanism of Action (blocks CGRP binding to the receptor).
Emgality blocks the CGRP molecule rather than the CGRP receptor.
Mechanism support exists that it blocks CGRP ligand binding to the receptor (12.1), though the 'rather than' contrast is non-label-precise (see contradictions).
Emgality is administered as a monthly subcutaneous injection.
Supported by 2.1 Recommended Dosing for Migraine (monthly doses of 120 mg injected subcutaneously).
Constipation occurs.
Supported by 6 ADVERSE REACTIONS (Constipation with Serious Complications) and 5.2 discussion.
Hypersensitivity occurs.
Supported by 6 ADVERSE REACTIONS (Hypersensitivity Reactions) and 5.1 discussion.
Emgality is approved for migraine prevention in adults.
Supported by 1 INDICATIONS AND USAGE (preventive treatment of migraine in adults).
In clinical trials, Emgality reduces monthly migraine days by about 4-5 for episodic and chronic migraine prevention.
No numeric results provided in the provided excerpts for Section 14; mechanism/indication text only.
Unsupported Statements
Emgality specifically targets and inhibits calcitonin gene-related peptide (CGRP).
Partially supported: label states it binds CGRP ligand and blocks its binding to the receptor; 'specifically targets and inhibits' is not verbatim and is more interpretive than the provided mechanism wording.
Emgality reduces migraine frequency.
Not explicitly supported by the provided label excerpts; provided indication text does not state 'reduces migraine frequency.'
In clinical trials, Emgality reduces monthly migraine days by about 4-5 for episodic and chronic migraine prevention.
Numeric effect size (4–5 monthly migraine days) is not contained in the provided label excerpts.
Injection-site reactions occur in up to 45% of patients.
No incidence/rate table for injection-site reactions is included in the provided label excerpts.
Allergic reactions are rare (under 2%).
No incidence/rate threshold for allergic reactions is provided in the supplied label excerpts.
Hypertension is rare (under 2%).
No incidence/rate threshold for hypertension is provided in the supplied label excerpts.
No black-box warnings apply.
Boxed warning presence/absence is not verifiable from the provided label excerpts.
Eli Lilly manufactures Emgality.
Manufacturer information is not present in the provided label excerpts.
Emgality was approved by the FDA in 2018.
Approval year/date is not present in the provided label excerpts.
Contradictions
Low
AI Statement
Emgality blocks the CGRP molecule rather than the CGRP receptor.
Label Reference
12.1 Mechanism of Action (blocks CGRP ligand binding to the receptor).
Important Omissions
Boxed warning status cannot be confirmed from provided excerpts; contraindications and other key safety sections are not evaluated/covered.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claimed safety incidence/rate thresholds (injection-site reactions, allergic reactions, hypertension) and boxed-warning absence are not supported by the provided label excerpts, which could mislead risk perception. Other safety warnings (hypersensitivity, constipation with serious complications, hypertension monitoring) are broadly consistent but not accurately quantified as claimed.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Aligned
Primary Issue
Multiple unsupported or non-verifiable claims, especially numerical incidence/rate statements and 'no black-box warnings' without boxed-warning section support; some mechanistic wording is non-label-precise ('rather than' contrast).
Suggested Improvement
Remove/replace unsupported numerical thresholds and ensure boxed-warning statements are supported by the actual boxed warning section text; rephrase mechanism using label wording (binds CGRP ligand and blocks CGRP binding to the receptor) and avoid 'rather than' contrasts not present in the label.